While the FDA has been monitoring the impact of the COVID-19 outbreak on drug supplies to the U.S., it turns out the Trump administration's ban on travel from Europe threatened to interrupt shipments of Novartis’ Kymriah gene therapy, delivery of which is time-sensitive.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,